Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Novartis : to Donate Drug in Coronavirus Fight

share with twitter share with LinkedIn share with facebook
share via e-mail
03/20/2020 | 11:46am EDT

By Giulia Petroni

Novartis AG said Friday that it would donate up to 130 million doses of generic hydroxychloroquine by the end of May to support the global response to the coronavirus pandemic.

The Swiss drug maker said hydroxychloroquine and a related drug, chloroquine, are currently being evaluated in clinical trials for the treatment of the virus. The company is exploring the possibility of increasing supply to meet global demand.

Novartis said its division Sandoz, which focuses on generic pharmaceuticals and biosimilars, holds a registration for hydroxychloroquine in the U.S. and will therefore pursue regulatory approval from the Food and Drug Administration and the European Medicine Agency.

It added that it would collaborate with the World Health Organization to determine the best distribution of the medicine on a global scale.

 

Write to Giulia Petroni at giulia.petroni@wsj.com

 

Stocks mentioned in the article
ChangeLast1st jan.
NOVARTIS AG 2.71% 83.38 Delayed Quote.-11.66%
WORLD CO., LTD. 4.87% 1616 End-of-day quote.-39.95%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS AG
06:13aFCA Gives Guidance For Common PM(NOC) Trials Involving Multiple Actions
AQ
01:38aNOVARTIS : data highlight benefit of early treatment initiation in patients with..
PU
05/27Rising Swiss rivalry as Roche and Novartis target same diseases
RE
05/26Timber Pharmaceuticals Lists To NYSE; Adds $20 Million And A Novel Pipeline T..
AQ
05/2610 YEARS OF BIOSIMILARS : Lessons And Trends
AQ
05/26Swiss foreign trade hit by coronavirus measures in April
RE
05/26NOVARTIS : study reveals that migraine support in the workspace can significantl..
PU
05/21GLOBAL MARKETS LIVE: Apple and Google unveil their Covid-19 contact tracing s..
05/21NOVARTIS AG : UBS reaffirms its Neutral rating
MD
05/20NOVARTIS : AveXis receives EC approval and activates 'Day One' access program fo..
AQ
More news
Financials (USD)
Sales 2020 50 047 M - -
Net income 2020 9 407 M - -
Net Debt 2020 17 505 M - -
P/E ratio 2020 20,3x
Yield 2020 3,72%
Capitalization 185 B 185 B -
EV / Sales 2019
EV / Sales 2020 4,04x
Nbr of Employees 109 000
Free-Float 84,4%
Chart NOVARTIS AG
Duration : Period :
Novartis AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVARTIS AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 100,39 $
Last Close Price 83,84 $
Spread / Highest target 54,5%
Spread / Average Target 19,7%
Spread / Lowest Target -8,19%
EPS Revisions
Managers
NameTitle
Vasant Narasimhan Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Werner Kirsch Chief Financial Officer
John Tsai Chief Medical Officer
Elizabeth Theophille Chief Technology & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS AG-11.66%184 492
JOHNSON & JOHNSON-0.67%381 726
ROCHE HOLDING AG5.76%291 889
PFIZER, INC.-4.52%207 806
MERCK & CO., INC.-14.73%195 744
ABBVIE INC.1.63%158 576